Emivirine: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
'''Emivirine''' (also known as MKC-442 or Coactinon) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was under investigation for the treatment of [[HIV/AIDS]]. Despite initial promise in early clinical trials, development of emivirine for clinical use was ultimately discontinued. This article provides an overview of emivirine, including its mechanism of action, clinical development, and the reasons for the cessation of its development.
{{Short description|Overview of the antiretroviral drug Emivirine}}
{{Drugbox
| image = Emivirine.png
| image_size = 250px
| image_alt = Chemical structure of Emivirine
| image_caption = Chemical structure of Emivirine
}}
 
'''Emivirine''' is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was investigated for the treatment of [[HIV/AIDS]]. Although it showed promise in early studies, it was never marketed.


==Mechanism of Action==
==Mechanism of Action==
Emivirine works by inhibiting the action of reverse transcriptase, an enzyme crucial for the replication of the [[Human Immunodeficiency Virus (HIV)]]. By binding to a specific site on the reverse transcriptase enzyme, emivirine prevents the transcription of viral RNA into DNA, a critical step in the HIV life cycle. This action is similar to that of other NNRTIs, but emivirine was noted for its unique chemical structure and its potential for a favorable resistance profile compared to other drugs in the same class.
Emivirine works by inhibiting the activity of [[reverse transcriptase]], an enzyme crucial for the replication of [[HIV]]. By binding to the reverse transcriptase enzyme, emivirine prevents the conversion of viral RNA into DNA, thereby halting the replication process of the virus within the host cells.
 
==Development and Clinical Trials==
Emivirine was developed in the 1990s and underwent several [[clinical trials]] to assess its efficacy and safety in treating HIV infection. Despite initial positive results, further studies revealed limitations in its effectiveness compared to other available NNRTIs, leading to the discontinuation of its development.
 
==Pharmacokinetics==
The pharmacokinetic profile of emivirine includes its absorption, distribution, metabolism, and excretion. Emivirine is orally bioavailable and is metabolized primarily in the liver. The drug's half-life and clearance rates were studied to optimize dosing regimens during its clinical evaluation.


==Clinical Development==
==Side Effects==
The development of emivirine was part of a broader effort to find effective treatments for HIV/AIDS, particularly drugs that could offer alternatives to those with existing drug resistance or intolerable side effects from other medications. Early phase clinical trials indicated that emivirine had a promising antiviral effect and was generally well tolerated by patients.
Like other NNRTIs, emivirine was associated with certain side effects. Common adverse effects included [[rash]], [[nausea]], and [[headache]]. More severe side effects were rare but included [[hepatotoxicity]] and [[hypersensitivity reactions]].


However, as development progressed, issues emerged that led to the discontinuation of emivirine's development. These included concerns about the drug's efficacy in larger, more diverse patient populations and the emergence of drug-resistant strains of HIV that reduced emivirine's effectiveness. Additionally, the competitive landscape of HIV treatment evolved rapidly, with the development of new drugs and drug classes that offered improved efficacy, safety, and convenience over emivirine.
==Comparison with Other NNRTIs==
Emivirine was compared with other NNRTIs such as [[efavirenz]], [[nevirapine]], and [[delavirdine]]. While it shared a similar mechanism of action, emivirine did not demonstrate superior efficacy or safety, which contributed to its lack of approval for clinical use.


==Discontinuation of Development==
==Current Status==
The decision to discontinue the development of emivirine was announced by the pharmaceutical company responsible for its development. This decision was based on a comprehensive review of the available data, which suggested that emivirine would not offer a significant advantage over existing treatments in terms of efficacy or safety.
As of now, emivirine is not used in clinical practice and is not available on the market. Research and development efforts have shifted towards other antiretroviral agents with better efficacy and safety profiles.


==Conclusion==
==Related pages==
While emivirine showed initial promise as a potential treatment for HIV/AIDS, its development highlights the challenges inherent in drug development, particularly for diseases as complex and variable as HIV. The discontinuation of emivirine's development serves as a reminder of the importance of ongoing research and innovation in the field of HIV/AIDS treatment, as well as the need for a diverse arsenal of therapeutic options to address the evolving landscape of the disease.
* [[HIV/AIDS treatment]]
* [[Non-nucleoside reverse transcriptase inhibitors]]
* [[Antiretroviral drug development]]


[[Category:HIV/AIDS]]
[[Category:Antiretroviral drugs]]
[[Category:Antiretroviral drugs]]
[[Category:Abandoned drugs]]
[[Category:Non-nucleoside reverse transcriptase inhibitors]]
 
== Emivirine ==
{{medicine-stub}}
<gallery>
File:Emivirine.png|Emivirine
</gallery>

Latest revision as of 23:56, 24 February 2025

Overview of the antiretroviral drug Emivirine


Emivirine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Emivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was investigated for the treatment of HIV/AIDS. Although it showed promise in early studies, it was never marketed.

Mechanism of Action[edit]

Emivirine works by inhibiting the activity of reverse transcriptase, an enzyme crucial for the replication of HIV. By binding to the reverse transcriptase enzyme, emivirine prevents the conversion of viral RNA into DNA, thereby halting the replication process of the virus within the host cells.

Development and Clinical Trials[edit]

Emivirine was developed in the 1990s and underwent several clinical trials to assess its efficacy and safety in treating HIV infection. Despite initial positive results, further studies revealed limitations in its effectiveness compared to other available NNRTIs, leading to the discontinuation of its development.

Pharmacokinetics[edit]

The pharmacokinetic profile of emivirine includes its absorption, distribution, metabolism, and excretion. Emivirine is orally bioavailable and is metabolized primarily in the liver. The drug's half-life and clearance rates were studied to optimize dosing regimens during its clinical evaluation.

Side Effects[edit]

Like other NNRTIs, emivirine was associated with certain side effects. Common adverse effects included rash, nausea, and headache. More severe side effects were rare but included hepatotoxicity and hypersensitivity reactions.

Comparison with Other NNRTIs[edit]

Emivirine was compared with other NNRTIs such as efavirenz, nevirapine, and delavirdine. While it shared a similar mechanism of action, emivirine did not demonstrate superior efficacy or safety, which contributed to its lack of approval for clinical use.

Current Status[edit]

As of now, emivirine is not used in clinical practice and is not available on the market. Research and development efforts have shifted towards other antiretroviral agents with better efficacy and safety profiles.

Related pages[edit]

Emivirine[edit]

  • Emivirine
    Emivirine
Retrieved from "https://wikimd.com/index.php?title=Emivirine&oldid=6343633"